Verona Pharma plc — Director's Dealing 2022

Sep 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2022-09-26

Reporting Person: Poll Claire (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-26	Ordinary Shares	A	800000	—	Acquired	2563055	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	483840	Indirect

Footnotes

F1: Reported securities are represented by American Depositary Shares ("ADSs") (unless otherwise indicated), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter.

F3: Consists of (i) 2,160,000 Ordinary Shares underlying RSUs (which may be represented by 270,000 ADSs); (ii) 403,048 Ordinary Shares underlying 50,381 ADSs; and (iii) 7 Ordinary Shares.

F4: Held by a family trust of which (a) the Reporting Person and spouse are trustees and (b) the Reporting Person and members of her immediate family are the sole beneficiaries of the trust.